

Mark G Lewis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1366055/publications.pdf>

Version: 2024-02-01

69
papers

13,396
citations

76294

40
h-index

91828

69
g-index

98
all docs

98
docs citations

98
times ranked

17387
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JV10159921.	1.5	5
2	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
3	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
4	Passive transfer of Ad26.COVS-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	2.9	2
5	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
6	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	2.2	11
7	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
8	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
9	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
10	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
11	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
12	Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. <i>Med</i> , 2022, 3, 262-268.e4.	2.2	117
13	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
14	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4
15	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
16	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
17	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. <i>Nature Communications</i> , 2022, 13, .	5.8	12
18	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. <i>Science</i> , 2022, 377, .	6.0	120

#	ARTICLE	IF	CITATIONS
19	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
20	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021, 12, 1474.	5.8	26
21	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46
22	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .	2.3	52
23	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
24	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. <i>Journal of Virology</i> , 2021, 95, .	1.5	21
25	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
26	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , 2021, 6, 83.	2.9	25
27	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
28	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
29	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , 2021, 6, 1188-1198.	5.9	314
30	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
31	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
32	Immunity elicited by natural infection or Ad26.COVS vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
33	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	5.8	15
34	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	6.0	244
35	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
36	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12

#	ARTICLE	IF	CITATIONS
37	Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. <i>Cell Reports Medicine</i> , 2021, 2, 100420.	3.3	28
38	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	68
39	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
40	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
41	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	2.9	47
42	Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 810047.	2.2	3
43	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 156.	2.9	15
44	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	1.5	19
45	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
46	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <i>Science</i> , 2020, 370, 1110-1115.	6.0	476
47	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
48	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. <i>Cell</i> , 2020, 183, 1354-1366.e13.	13.5	184
49	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
50	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
51	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.	15.2	275
52	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
53	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
54	Lack of therapeutic efficacy of an antibody to $\hat{1}\pm$ $\hat{2}$ $\hat{3}$ $\hat{4}$ $\hat{5}$ $\hat{6}$ $\hat{7}$ $\hat{8}$ $\hat{9}$ $\hat{0}$ in SIVmac251-infected rhesus macaques. <i>Science</i> , 2019, 365, 1029-1033.	6.0	31

#	ARTICLE	IF	CITATIONS
55	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019, 366, .	6.0	118
56	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	133
57	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
58	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	4.2	366
59	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017, 543, 248-251.	13.7	699
60	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , 2017, 169, 610-620.e14.	13.5	191
61	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
62	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. <i>Nature Medicine</i> , 2016, 22, 1448-1455.	15.2	270
63	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
64	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	6.0	461
65	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
66	Envelope residue 375 substitutions in simianâ€“human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
67	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
68	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	13.7	527
69	Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003658.	2.1	76